Aktienanalyse zu Shattuck Labs Inc (STTK)STTKShattuck Labs Inc

Shattuck Labs, Inc. is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is engaged in developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. It is conducting a Phase I clinical trial in healthy volunteers. It is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Shattuck Labs Inc is currently not a strong buy due to its recent price decline of 9.21% over the last five days and an RSI of 33.81, indicating it is oversold. However, the positive analyst sentiment, with a strong buy rating and a price target of $18 from Raymond James, suggests potential for recovery. The main risk is the company's ongoing losses, with a net income of -15,152,000 USD in Q2 2026, which could impact its financial stability.